Airway smooth muscle GPCR
human individuals. In addition, this murine model was exposed to allergens (ovalbumin or house dust mite extract) to decipher in vivo the implication of Rac1 in AHR. Results: The specific SMC deletion or pharmacological inhibition of Rac1 in mice prevented the bronchoconstrictor response to methacholine. In human bronchi, a similar role of Rac1 was observed during bronchoconstriction. We further demonstrated that Rac1 activation is responsible for bronchoconstrictor-induced increase in intracellular Ca 21 concentration and contraction both in murine and in human bronchial aSMCs, through its association with phospholipase C b2 and the stimulation of inositol 1,4,5-trisphosphate production. In vivo, Rac1 deletion in SMCs or pharmacological Rac1 inhibition by nebulization of NSC23766 prevented AHR in murine models of allergic asthma. Moreover, nebulization of NSC23766 decreased eosinophil and neutrophil populations in bronchoalveolar lavages from mice with asthma. Conclusions: Our data reveal an unexpected and essential role of Rac1 in the regulation of intracellular Ca 21 and contraction of aSMCs, and the development of AHR. Rac1 thus appears as an attractive therapeutic target in asthma, with a combined beneficial action on both bronchoconstriction and pulmonary inflammation. (J Allergy Clin Immunol 2018;142:824-33.)
Key words: Rac1, airway smooth muscle, asthma, airway hyperresponsiveness, calcium, PLC, pulmonary inflammation Allergic asthma is a major public health problem characterized by inflammation and chronic bronchial obstruction associated with airflow alteration. 1, 2 The major cause of morbidity and mortality from the disease is airway obstruction, which depends on both tissue remodeling 3, 4 and airways hyperresponsiveness (AHR) [5] [6] [7] due to excessive contraction of airway smooth muscle cells (aSMCs) of the bronchial wall and inflammation. 8 Indeed, AHR results from a complex crosstalk between immune and bronchial wall cells, driven by a network of cytokines, growth factors, and bronchoconstrictors. The degree of AHR correlates with asthma severity and the need for therapy. Current treatments consist in inhaled combination of long-acting beta-adrenergic receptor agonist for bronchodilation and anti-inflammatory corticosteroids. However, 5% to 10% of patients with severe asthma are refractory to these available medications and remain at high risk of serious morbidity and life-threatening asthma attacks. 9 As intracellular signaling molecules activated by extracellular stimuli, small GTPases of the Rho family (RhoA, Rac1, and Cdc42) act as molecular switches that regulate signaling cascades controlling SMC functions. 10 Increasing evidence implicates the Rho protein Rac1 in the regulation of vascular SMC contraction, 11, 12 and genetic deletion of Rac1 regulator 13 or effector 14 has been shown to modulate AHR in experimental allergic models. Furthermore, Rac1 has been identified last year as a potential link between pulmonary inflammation and bronchoconstriction. 15 Thus, we hypothesized that SM Rac1 could play an essential role in bronchoconstriction and during AHR associated with allergic asthma. To elucidate Rac1 functions in aSMCs, we used a mouse model of SMC-specific Rac1 deletion at adult stage. 11 Notably, we observed that bronchi from these mice failed to develop contraction. We further demonstrate, in human and murine aSMCs, that Rac1 is activated by bronchoconstrictor and plays a major role in the rise in intracellular Ca 21 concentration through the control of PLC activity. In addition, we observed that inhibition of Rac1 activity prevents AHR-induced allergic asthma in mice, suggesting that Rac1 inhibition is a new therapeutic strategy against asthma.
METHODS Mice
All experimental procedures and animal care were performed in accordance with the Regional Ethical Committee for Animal Experiments of the Pays de la Loire. C57Bl/6 Rac1 lox/lox and SMMHC-Rac1 lox/lox mice were obtained as previously described.
11 Rac1 deletion in smooth muscle cells (SMCs) was induced in 8-week-old SMMHC-Rac1 lox/lox males by intraperitoneal injection of tamoxifen (1 mg/d in sunflower oil) for 5 consecutive days during 2 weeks. Tamoxifen-treated Rac1 lox/lox mice were used as control. Analyses were performed 1 month after tamoxifen treatment.
To validate Rac1 deletion in aSMCs, DNA Rac1 status was analyzed in trachea and liver by amplification of the wild-type, floxed, and deleted Rac1 alleles using 3 primers simultaneously: Reverse: 59-TCCAATCTGTGCTGCC CATC-39; Forward1: 59-CAGAGCTCGAATCCAGAAACTAGTA-39; and Forward2 59-GATGCTTCTAGGGGTGAGCC-39. All 3 primers were included in a single PCR and yielded PCR products of 115 bp (wild-type), 140 bp (Rac1 deleted), and 242 bp (Rac1 floxed). Detection of Rac1 mRNA was performed in tracheal and bronchial sections by in situ hybridization as described previously, 11 using immunohistochemical detection of SM22a to detect SMCs.
Human airways
Human bronchi were obtained from donor tissues. Tissues were collected in physiologic saline solution and used for primary airway SMC culture or airways reactivity ex vivo.
Cell culture
Primary aSMCs were isolated from primary bronchi of the indicated mouse strain or from human biopsies. Tissues were cleaned manually and the muscular layer was further digested for 1 hour with collagenase II (1 mg/mL, Worthington Biochemical, Lakewood, NJ) at 378C under agitation. Cells grew up in Dulbecco modified Eagle medium (Gibco; Invitrogen ThermoFisher Scientific, Waltham, Mass) containing 10% FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin at 378C and 5% CO 2 . The culture medium was changed every 72 hours. All experiments were performed between passages 1 and 2. Primary vascular SMCs were isolated and cultured as described previously. 16 
Immunoblotting
Tissues or primary SMCs in culture were incubated on ice with lysis buffer supplemented with proteases and phosphatases inhibitor cocktails (Sigma Aldrich, Saint Quentin Fallavier, France) and sodium orthovanadate. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose membranes, and incubated with specific antibodies. Rac1 antibody (610651) was from BD Biosciences (Le Pont de Claix, France) PLCb2 (129889) was from Abcam (Paris, France). MYPT1 (2634), p-MLC2 (3671), MLC2 (3672), p-Pak (2605), and Pak1 (2602) antibodies were from Cell Signaling Technology (Leiden, The Netherlands). p-MYPT (sc17556) antibody was from Santa Cruz Biotechnology (Heidelberg, Germany) and tubulin from Beckman Coulter (Villepinte, France). Immune complexes were detected with appropriate secondary antibodies and enhanced chemiluminescence reagent (Clarity ECL BioRad, Marnes la Coquette, France). Protein band intensities were quantified using ImageJ Software (NIH software, Bethesda, Md). Coimmunoprecipitation of PLCb2 with Rac1 was carried out using anti-Rac1 or anti-PLCb2 antibodies (1 mg) incubated with Protein A magnetic beads for 1 hour at 48C according to the supplier's specifications (mMacs Protein A/G Microbeads MultiMACS Protein A/G Kit, Miltenyi Biotec, Paris, France).
Analysis of Rac1 activity
In human or murine aSMC lysates, Rac1 activity was evaluated by active Rac immunoprecipitation using anti-Rac-GTP antibody (26903, NewEast Biosciences, King of Prussia, Pa). The precipitated active Rac was subjected to SDS-PAGE and detected by immunoblot with anti-Rac1 antibody (BD Biosciences). In pulmonary paraffin-embedded sections, Rac-GTP levels were detected by immunofluorescence. Sections were deparaffinized and permeabilized (PBS 1 0.1% Triton-X100) before incubation with anti-Rac-GTP antibody (1/500) overnight at 48C. After 3 washes in PBS, sections were incubated for 1 hour at room temperature with the secondary Alexa568-labeled anti-mouse antibody (1/1000).
Intracellular calcium measurements
Murine and human aSMCs were seeded at 2 3 10 4 cells/well in 8-chamber borosilicate coverglass (Lab-Tek, ThermoFisher Scientific). Rac1 lox/lox cells were treated or not with 4-hydroxy-tamoxifen (1 mM, 48 hours) to induce Rac1 deletion in SM-Cre positive cells (smooth muscle cell-specific Rac1 knockout [SMC-Rac1-KO] mice). FluoForte probes were loaded using FluoForte calcium assay kit (Enzo Life Science, Villeurbanne, France) according to the supplier's specifications. When indicated, Rac1 inhibitor NSC23766 (10 mM), IP3 receptor antagonist 2-ABP (10 mM), and PLC inhibitor U73122 (10 mM) were added 1 hour before loading probes. After basal fluorescence recording, cells were stimulated with carbachol (CCh) (30 mM). The fluorescence was recorded using Metamorph software and quantified with ImageJ Software (NIH software).
IP3 assay
Murine and human aSMCs were used to measure IP3 content after indicated treatments according to manufacturer's protocol (HitHunter IP3 Fluorescence Polarization Assay, DiscoverX, Birmingham, United Kingdom).
Airways reactivity ex vivo
Murine and human primary bronchi or murine trachea were cleaned, cut in rings, and mounted on a multichannel isometric myograph in Krebs-Henseleit physiological solution (118.4 mM NaCl, 4.7 mM KCl, 2 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 , and 11 mM glucose) at 378C under oxygen. A pretension of 0.5 mN was applied. We constructed dose-response curves to methacholine (Sigma-Aldrich, Paris, France). When indicated, rings were preincubated 1 hour before contraction with PLC inhibitor U73122 (Tocris, Lille, France), IP3R inhibitor 2-ABP (Tocris), or PAK inhibitor IPA3 (Tocris) at 10 mM. To inhibit Rac activity ex vivo, we observed that NSC23766 should be incubated for 12 hours with bronchial rings. In contrast, the Rac inhibitor EHT1864 (Sigma) induced an efficient activity at 10 25 mol after 1 hour of incubation (see Fig E2, A, in this article's Online Repository at www.jacionline.org). Thus, to limit incubation time, EHT1864 (Sigma) was selected to analyze airways reactivity ex vivo. The wire myograph was connected to a digital data recorder (MacLab/4e, AD Instruments, Paris, France) and recordings were analyzed using LabChart v7 software (AD Instruments).
Airways responsiveness measurement in vivo
Airway responsiveness was assessed in conscious, unrestrained mice using a barometric, whole-body plethysmography (EMKA Technologies, Paris, France) by recording respiratory pressure curves in response to inhaled methacholine (Sigma) at concentrations of 0 to 40 mg/mL for 1 minute. Airway responsiveness was expressed in enhanced pause (P enh ) units. The P enh values measured after stimulation were averaged and expressed as the foldincrease over baseline values. Alternatively, dynamic airway resistance was measured using an invasive FlexiVent apparatus (SCIREQ). In these analyses, mice were anesthetized (ketamine/xylazine), paralyzed (rocuronium bromide), tracheotomized, and mechanically ventilated (150 breaths/min). Increasing concentrations of methacholine were administered via a nebulizer aerosol system (Aeroneb, Aerogen, Dangan, Galway, Ireland). When required, the Rac inhibitor NSC23766 (Tocris) and salbutamol were nebulized (300 mL at 5 mM) 10 minutes before methacholine challenge.
Respiratory parameters
Mice were placed in physiocages (Bioseb, Vitrolles, France) to measure gas exchanges during 24 hours after a 2-day acclimatizing period. The recording room was maintained with a 12-hour-light/12-hour-dark cycle.
Allergic asthma models
Allergic asthma was induced in mice using a total house dust mite extract (house dust mite extract Dermatophagoides farinae [Der f], from Stallergenes Greer, Antony, France) as described previously. 15 Briefly, mice were sensitized on days D0, D7, D14, and D21 by skin application of 500 mg Der f in 20 mL of dimethyl sulfoxide (Sigma) onto the ears. Control mice were sensitized with dimethyl sulfoxide. Intranasal challenges were performed with 250 mg of Der f in 40 mL of sterile PBS on D27 and D34. When indicated, allergic asthma was induced using ovalbumin (OVA) model. Ten microgram of OVA (A5503, Sigma) was administrated by intraperitoneal injections in alum vehicle (77161, Thermo scientific) on days D0, D14, and D21. Mice were then challenged through intranasal route with aerosolized OVA (50 mg in PBS) on D27, D28, and D29. Control mice were sensitized with PBS/alum. When indicated, allergic asthma mice were treated by repeated inhalations of NSC23766 or salbutamol (5 mM in PBS) before each challenge and methacholine nebulization. All mice were sacrificed 24 hours after last intranasal challenge for analysis.
Bronchoalveolar lavage fluid analysis
Mice were tracheotomized and 1 mL of sterile PBS was administrated intratracheally through a catheter. Cells and supernatants from recovered fluid were separated by centrifugation. Total cell number was counted on Kova slides by optical microscopy. Identification of immune cell subpopulations was performed by flow cytometry analysis. 15 Acquisition was performed on LSR II (BD Bioscience) and analyzed with FlowJo software.
Histology
Paraformaldehyde (4% in PBS, 1 mL) was administered intratracheally in the lungs through a flexible catheter, trachea was ligatured, and lungs were excised. Lungs were fixed in 4% paraformaldehyde for 48 hours and embedded into paraffin. Sections measuring 6 mm in size were stained with periodic acid-Schiff or hematoxylin/eosin for morphological studies. Histological grade was determined to assess inflammation and pulmonary remodeling. 15 
Statistics
All data are expressed as the mean 6 SEM of sample size n. For multiple comparisons, the nonparametric Kruskal-Wallis test was used followed by Dunns' posttest. For individual comparisons, statistical analysis was performed using nonparametric t test (Mann-Whitney). Data analysis was performed using the GraphPad Prism software. The threshold for statistical significance was set at P < .05.
RESULTS

Inhibition of Rac1 expression or activity prevents bronchoconstriction in human and mice airways
To elucidate the specific functions of Rac1 in SMCs, we generated tamoxifen-inducible and SMC-Rac1-KO mice. 11 In situ hybridization and western blot analysis confirmed the loss of Rac1 mRNA and protein expression in aSMCs, which did not affect normal respiratory function under basal condition (see Fig E1 in this article's Online Repository at www.jacionline.org). We first studied the functional impact of Rac1 deletion in aSMCs by measuring the contractile response of bronchial rings from control (Rac1 lox/lox ) and SMC-Rac1-KO mice. The maximal contraction induced by the muscarinic receptor agonist methacholine was reduced by approximately 50% in bronchial rings from SMC-Rac1-KO mice compared with Rac1 lox/lox mice (Fig 1, A) . This inhibitory effect of SMC Rac1 deletion on methacholine-induced bronchoconstriction was mimicked by the pharmacological Rac inhibitors (EHT1864 and NSC23766) in bronchial rings from control mice and humans (Fig 1, A, and Fig E2, A) . Similarly, the bronchoconstriction induced by serotonin was reduced by approximately 70% in murine bronchial rings incubated with EHT1864 (Fig E2, B) .
To confirm in vivo the role of Rac1 in bronchoconstriction, we next measured the pulmonary resistance in control and SMC-Rac1-KO mice. Although the baseline resistance was similar in the 2 groups, aerosolized methacholine-induced increase in pulmonary resistance was significantly smaller in SMC-Rac1-KO mice than in control mice (Fig 1, B) . Consistent with this result, inhalation of the Rac inhibitor NSC23766 in control mice decreased methacholine-induced bronchoconstriction with an efficacy similar to salbutamol, a reference bronchodilator used by patients with asthma (Fig 1, B) . In contrast, inhalation of NSC23766 in SMC-Rac1-KO mice had mice (n 5 6-8). When indicated, rings were pretreated with the Pak1 inhibitor IPA3 or the Rac inhibitor EHT1864. AU, Arbitrary units. Data are expressed as mean 6 SEM. *P < .05 and **P < .01 vs control, $ P < .05 vs CCh.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 3 no effect on methacholine-induced bronchoconstriction (data not shown), demonstrating the specific inhibition of NSC23766 on Rac activity. These results suggest that Rac1 plays a major role in aSMC contraction in vivo.
Bronchoconstrictors stimulate Rac1/phospholipase C b2 association to modulate intracellular Ca 21 
concentration in aSMCs
We next sought to identify the mechanism by which Rac1 controlled aSMC contraction by first analyzing the activity of Rac1 and its main effector, p21-activated kinase 1 (Pak1). Stimulation of murine and human aSMCs with the muscarinic cholinergic receptor agonist CCh increased Rac1 and Pak1 activity (Fig 1, C) . NSC23766 treatment prevented Pak1 activation, indicating that muscarinic receptor stimulation turns on Rac1 and its downstream effector Pak1 in aSMCs. The Pak inhibitor IPA3 had no significant effect on muscarinic receptor stimulation-induced contraction of mouse bronchial rings and only a weak inhibitory effect on tracheal rings (Fig 1, D) , as previously described.
14 However, both bronchial and tracheal contractions were similarly reduced by pharmacological Rac1 inhibition (Fig 1, D) , suggesting that the effect of Rac1 in bronchoconstriction is independent of Pak1.
We next examined the status of 2 essential signaling pathways involved in SMC contraction: Ca 21 sensitization and Ca 21 signaling pathways. 10 Stimulation of murine and human aSMCs by CCh, in the absence or in the presence of Rac1 inhibitor, did not significantly affect the level of phosphorylated myosin phosphatase target subunit (MYPT), suggesting that the activity of the myosin light chain phosphatase was not modified and the Ca 21 -sensitization pathway not activated (Fig 1, C) . In contrast, the CCh-induced rise in intracellular Ca 21 in control murine and human aSMCs was abolished by Rac1 deletion or inhibition Data are expressed as mean 6 SEM. *P < .05, **P < .01, and ***P < .001 vs control; $ P < .05 and $$ P < .01 vs CCh-treated cells. (Fig 2, A) , suggesting that Rac1 regulates bronchial contraction by controlling intracellular Ca 21 signaling. Activation of phospholipase C b, production of inositol 1,4,5-trisphosphate (IP 3 ), and opening of IP 3 receptor-Ca 21 release channels of the sarcoplasmic reticulum are the main mechanisms activated by G-protein-coupled receptor agonists to induce cytosolic Ca 21 increase in SMCs. 17 To understand how Rac1 regulates intracellular Ca 21 , we thus used inhibitors of PLC (U73122) and IP 3 receptor (2-ABP). Both U73122 and 2-ABP prevented muscarinic receptor activation-induced intracellular Ca 21 rise in aSMCs and constriction of bronchial rings from control mice, but had no effect in aSMCs and bronchial rings from SMC-Rac1-KO mice (Fig 2, B, and Fig E2, B) . Consistent with this observation, we found that CCh promoted production of IP 3 in murine and human aSMCs that was abolished by the PLC inhibition (U73122), and in a similar extent, by the Rac inhibitor NSC23766 (Fig 2, C) . Interestingly, we observed that 5HT-dependent bronchoconstriction is also sensitive to inhibitors of PLC (U73122) and IP3 receptor (2-ABP) (Fig E2, C) . These results unveil a key role of Rac1 activity in the PLC/IP 3 signaling coupling bronchoconstrictor receptor to cytosolic Ca 21 rise in aSMC and contraction. In recombinant systems and in vitro assays, active Rac1, 2, and 3 have been shown to interact with PLCb2 isoform. [18] [19] [20] Although PLCb2 expression was weak in murine vascular SMCs, aSMCs highly expressed the PLCb2 isoform and CCh stimulation increased its association with Rac1 (Fig 2, D and E) . This effect was blocked by NSC23766, suggesting that Rac1-PLCb2
Methacholine (mg/mL) . Nuclei were detected by DAPI staining. Scale bar, 100 mm. B, Analysis of airway reactivity to methacholine challenges by invasive methods (FlexiVENT) in naive (DP) and Der f-challenged mice (Der f) treated with NSC23766 or vehicle (NaCl) nebulization (n 5 5-8). Data are expressed as mean 6 SEM. *P < .05 vs DP NaCl; $ P < .05 vs Der f NaCl. C, Analysis of airway reactivity to methacholine challenges by invasive methods (FlexiVENT) in control Rac1 lox/lox and SMC-Rac1-KO mice challenged with Der f (n 5 5-8). Data are expressed as mean 6 SEM; *P < .05 vs control. D, Contractile responses to methacholine in bronchi rings from naive (DP) and Der f-sensitized mice (Der f) (n 5 6) preincubated with the Rac1 inhibitor EHT1864. DAPI, 49-6-diamidino-2-phenylindole, dihydrochloride. Data are expressed as mean 6 SEM. *P < .05 vs DP NaCl mice; $ P < .05 vs Der f NaCl.
association required Rac1 activation (Fig 2, E) . To confirm these results, we transiently expressed wild-type Rac1 (Rac1 WT ), a constitutively active (Rac1 V12 ), or a negative (Rac1 N17 ) Rac1 mutant in 3T3 cells and assessed their interaction with PLCb2 (Fig 2, F) . The amount of Rac1 WT immunoprecipitated with PLCb2 was increased by CCh stimulation. The Rac1 V12 mutant was constitutively associated with PLCb2 and CCh did not increase this association. In contrast, there was no interaction between PLCb2 and Rac1 N17 both in the absence or in the presence of CCh. These results demonstrate for the first time the association of endogenous PLCb2 with active Rac1 and its critical role in inducing IP 3 production, cytosolic Ca 21 rise, and aSMC contraction in response to bronchoconstrictor.
Inhibition of Rac1 expression or activity protects from AHR
We thus hypothesized that Rac1 could be causally involved in the excessive pathological bronchoconstriction associated with asthma. To assess this hypothesis, we first measured airway Rac1 activity in a mouse model of human allergic asthma, induced by percutaneous sensitization and intranasal challenge with Der f. 15 Exposure to Der f resulted in an increase in Rac1 activity in bronchi and peribronchial inflammatory cells that was inhibited by repeated NSC23766 nebulizations (Fig 3, A) . Der f sensitization induced AHR that was prevented by acute NSC23766 nebulization (Fig 3, B) and SMC Rac1 deletion (Fig 3, C) , suggesting a role of Rac1 activation in AHR. Ex vivo measurements of tension response to methacholine demonstrated the increased contraction of bronchial rings from Der f sensitized-mice compared with naive animals, and the inhibitory action of the Rac inhibitor EHT1864 confirmed that allergic asthma-associated excessive bronchoconstriction and AHR is dependent on Rac1 activity (Fig 3, D) .
Rac inhibitor inhalation prevents pulmonary inflammation in murine allergic asthma models
Histological analysis of lung sections showed that Der f-induced AHR was associated with massive mucus production and strong cellular infiltration of the airways that were similar in control and SMC-Rac1-KO mice (Fig 4) . These results indicate that aSMC Rac1 is not involved in lung inflammation associated with allergic asthma. However, we observed that repeated NSC23766 inhalations not only prevented AHR but also reduced inflammatory cell infiltration and airway remodeling in Der f-sensitized mice (Fig 5) . Rac inhibition in Der f-sensitized mice decreased eosinophil and neutrophil influx in bronchoalveolar lavage (Fig 5, C) . We observed the similar combined bronchodilator and anti-inflammatory effect of repeated NSC23766 treatment in OVA-induced mice with asthma (see Fig E3 in of NSC23766 on OVA-induced AHR was similar to that obtained with the reference bronchodilator salbutamol (Fig E3, A) , which had no action on inflammation (Fig E3, D) .
DISCUSSION
Taken together, our results greatly extend our understanding of the role of Rac1 in the control of murine and human aSMC contraction and have direct translational implications in asthma treatment. Our data establish that Rac1, acting through PLCb2, links bronchoconstrictor G-protein-coupled receptors to intracellular Ca 21 signaling and contraction. By a screen of 17 members of the Rho protein family in recombinant systems in COS-7 cells, only the active forms of Rac (Rac1, Rac2, and Rac3) have been identified to be able to bind PLCb2 and stimulate PLCb activity, thus defining PLCb2 as a Rac1 effector. 19 This direct interaction between active GTP-bound Rac1 and PLCb2 has been confirmed by the description of the crystal structure of the complex, demonstrating that Rac1 engages the pleckstrin-homology domain of PLCb2 to optimize its orientation for substrate membranes. 20 However, until now, the existence of such interaction of native proteins in endogenous systems and its role in the regulation of biological/physiological/ pathophysiological processes have never been described. Here, we demonstrate that stimulation of murine and human muscarinic cholinergic receptor in aSMCs increased Rac1 activity and promoted its association with PLCb2. Activation of Rac1 leads to its translocation from the cytosol to the plasma membrane. 21 Interestingly, a direct interaction between muscarinic receptor and PLCb leading to a close spatial proximity to both its substrate, PIP2, and its activator, Gaq, has been recently described in CHO cells. 22 This observation thus suggests that muscarinic receptor stimulation induces Rac1 activation and its translocation at the plasma membrane promoting Rac1/PLCb2 interaction. Our results further show that this protein interaction is necessary to potentiate IP 3 production, and consequently intracellular Ca 21 rise and contraction in murine and human aSMCs.
Studies focused on the role of Rac1 in SMC contraction by the use of pharmacological tools and genetic mouse models have produced conflicting data, reporting relaxing and contracting effects of Rac1 activity. Rahman et al 23 observed that pharmacological inhibition of Rac1 reduced or potentiated the contraction in different visceral SM tissues (urinary bladder and ileum) and arteries, depending on the contracting agonist used. 23 For example, Rac inhibition by NSC23766 in mouse saphenous artery had no effect on KCl-induced contraction, decreased the contractile response to phenylephrine, and potentiated the contraction induced by thromboxan A2 receptor stimulation. However, the specific depletion of Rac1 expression in vascular SMCs demonstrates that the activation of Rac1 promotes vasorelaxation by positively regulating cyclic guanosine monophosphate-dependent signaling. 11, 12 Inconsistent observations have also been reported in airway SMCs because Data are expressed as mean 6 SEM. **P < .01 and ***P < .001 vs DP NaCl mice;
relaxing properties have been ascribed to Rac1 activity in guinea pig trachea, 24 while activation of Pak1, the main effector of Rac1, has been associated with contraction of murine tracheal segments and human bronchial rings.
14 These results suggest that the regulation of Rac1 activity by contracting agonists, its downstream target effectors, and consequently its functions in the regulation of SMC contraction could be different according to SMC type and/or species. Different pattern of expression of intracellular signaling molecules in different SMCs might support, at least in part, the inconsistent role of Rac1 in the regulation of SMC contraction. The essential role of PLCb2 unveiled by our study fits with this hypothesis. We demonstrated that the connection between Rac1 and the PLCb2/Ca 21 signaling is responsible for the role of Rac1 in human and murine bronchial smooth muscle contraction. Accordingly, this new signaling pathway is expected to be essential particularly in SMCs that strongly express the PLCb2 isoform, as in human aSMCs.
In addition to its role in aSMC contraction, we demonstrate that Rac1 is activated in airways from murine model of asthma. Deletion of the Rac1 gene in SM or pharmacological Rac1 inhibition prevented AHR, highlighting the potential of targeting Rac1 in asthma in humans. We observe that Rac inhibitors decreased basal pulmonary function (Fig 1, B) and airway contractility (Fig 3, D) but do not affect airway resistance (Fig 3, B) . This apparent discrepancy is probably due to the experimental procedure. Indeed, the analysis of respiratory function was performed in conscious mice, while mice were anesthetized, paralyzed, tracheotomied, and mechanically ventilated to evaluate airway resistance. All these procedures could alter airway reactivity and mask NSC23766 and EHT1864 effects.
Long-acting muscarinic antagonists have been shown to produce beneficial effects on airway tone, smooth muscle contraction, mucus secretion, and vasodilation, 25, 26 and on patients with symptomatic asthma. [27] [28] [29] As we found that muscarinic receptor stimulation induced Rac1 activation, these positive actions of long-acting muscarinic antagonists could result, at least in part, from a reduced Rac1 activation and Rac1-mediated effects. However, despite the availability of therapies combining inhaled corticosteroids to reduce inflammation and long-acting b 2 -receptor agonist or longacting muscarinic antagonists to limit AHR, asthma control remains suboptimal for many patients who are resistant to these treatments. 30 Interestingly, inhalation of Rac inhibitors not only prevented AHR by inhibiting SMC Rac1 but also decreased pulmonary inflammation, probably by blocking Rac activity in immune/inflammatory cells. In fact, activation of Rac in leukocytes has been described to be involved in respiratory inflammation, 13, 15, 31 and it is well established that allergic asthma-associated airway inflammation is involved in AHR. 15, 32 Rac has also been reported to control epithelial barrier function and although specific deletion of Rac1 in the epithelial cells did not affect the integrity of the airway epithelium in vivo in basal condition, it exacerbated inflammation and augmented T H 2 cytokines in asthma models induced by house dust mite extract or OVA as allergens. 33 This effect has been ascribed to defective clearance of apoptotic cells by Rac1-deficient epithelial cells. One would thus expect that Rac inhibitors, which inhibit Rac1 in all cell types, including bronchial epithelial cells, would also produce an aggravation of allergic inflammation. In fact, we did not observe such increase in allergic airway inflammation after treatment of allergic mice with pharmacological Rac1 inhibitors, which, in contrast, reduced lung inflammation. However, our result is in agreement with a protective role of Rac inhibitors already described in pulmonary inflammation and asthma. 13, 34 In summary, our results in mice and human tissues reveal a new and fundamental role of Rac1 to promote aSMC contraction and AHR. Rac1 inhibition simultaneously prevents both AHR and pulmonary inflammation, offering the opportunity to aggregate in a single molecule the desired anti-inflammatory and bronchodilatory actions of antiasthma therapy. The development of Rac inhibitors could thus open up a new avenue for the treatment of pulmonary pathologies characterized by AHR and inflammation.
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Clinical implications: The nebulization of Rac inhibitor prevents AHR in murine models of allergic asthma, with the additional advantage to also decrease pulmonary inflammation. Rac1 thus appears as a new attractive therapeutic target in asthma. A, Analysis of airway reactivity to methacholine challenges by noninvasive plethysmography in mice (n 5 9-10) challenged with OVA (o/o) or alum vehicle (ap/ap). When indicated, mice were treated with either salbutamol, the Rac inhibitor NSC23766, or the vehicle NaCl. B, Airway reactivity to methacholine measured by FlexiVENT in naive and OVA-challenged mice pretreated with NSC23766 or vehicle (NaCl) (n 5 5-6). C, Histological sections and grades of lungs from naive (ap/ap) and OVA-sensitized (o/o) mice treated by repeated inhalations of NSC2366 or vehicle (NaCl). Sections are representative of 5 to 6 lungs in each experimental group. Upper panels, hematoxylin/eosin (HE) staining. Lower panels, periodic acid-Schiff (PAS) staining. Scale bars, 100 mm. D, Infiltrating cells in BAL fluid of naive (ap/ap) and OVA-sensitized mice (o/o) submitted to NSC23766, salbultamol, or NaCL (vehicle) treatments (n 5 5-6 in each experimental group). BAL, Bronchoalveolar lavage. Data are expressed as mean 6 SEM. *P < .05 and **P < .01 vs ap/ap NaCl, $ P < .05 vs o/o NaCl.
